Eli Lilly: In a Type 2 diabetes trial, the company's oral GLP-1 drug Orforglipron outperformed Novo Nordisk's oral Semaglutide in blood sugar control and weight loss.
Eli Lilly: In a Type 2 diabetes trial, the company’s oral GLP-1 drug Orforglipron outperformed Novo Nordisk’s oral semaglutide in blood sugar control and weight loss.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Eli Lilly: In a Type 2 diabetes trial, the company's oral GLP-1 drug Orforglipron outperformed Novo Nordisk's oral Semaglutide in blood sugar control and weight loss.
Eli Lilly: In a Type 2 diabetes trial, the company’s oral GLP-1 drug Orforglipron outperformed Novo Nordisk’s oral semaglutide in blood sugar control and weight loss.